Background:
HIV cure approaches involving in vivo gene therapy have the potential to target prominent tissue-resident HIV reservoirs. Virus-based vectors are most common in clinical studies, with Adeno-associated Virus (AAV) being the vector of choice. Effectiveness of in vivo gene therapy largely correlates with high vector doses, but must be balanced to avert unwanted effects including immune responses and transgene activity in non-target cells. Modulating receptor binding specificities of therapeutic vectors increases on-target effectivity while reducing off-target effects. So far, no robust viral gene therapy vector specific for CD4-positive HIV target cells has been described. We here show that coupling of AAV capsid surfaces with CD4-specific nanobodies mediates retargeting of AAVs to CD4-positive cells. These CD4-AAVs could provide an invaluable vector for anti-HIV therapeutic approaches.
Methods:
We used structure-based rational design to genetically fuse CD4-specific nanobodies into AAV capsid proteins VP1 and VP2. We examined optimal nanobody/insertion-site combination for targeted reporter transgene delivery in vitro and in vivo. We applied our engineering platform to multiple AAV serotypes, proving system versatility. Electron microscopy (EM) and biochemistry analyses were used to investigate particle characteristics.
Results:
Functional competition assays with CD4-AAV vectors revealed highly specific transduction of CD4-positive cells in vitro. Isolated human primary CD4-positive T cells from multiple donors are effectively transduced compared to wild-type AAV serotypes. CD4-positive cells were transduced with 5-fold higher specificity compared to CD4-negative cells in vitro. CD4-specific transduction was also observed in humanized mice after IV delivery. EM and biochemical characterization of CD4-AAV particles revealed overall beneficial features: regular morphology, increased capsid stability, nanobody presentation on the capsid outer shell, exceeding titers and unaffected genome packaging compared to wild-type AAVs.
Conclusions:
We provide proof-of-concept for a novel AAV-based vector platform with high specificity towards CD4-positive cells. These nanobody-engineered AAVs further preserve all beneficial AAV vector characteristic. Adaptation to other serotypes and exchange of nanobodies is straightforward. In combination with Crispr/Cas modules or HIV-specific recombinases, we proposed CD4-AAV vectors as valuable tool for safe and efficient anti-HIV in vivo gene therapy approaches.